Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (555)	7/16/2001 6:38:23 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 2243

ditto for "2001", take photo now if desired...... shown below...... (please remember that actual "current value" is actually the sum of cash plus "current value" as shown.... that is, the current value as now shown is greater than actual.)

To: scaram(o)uche who wrote (555)	12/17/2001 2:26:38 PM
From: quidditch	Read Replies (2) \| Respond to of 2243

Richard -- Little comment on this thread since you elected to add to each of 2000 and 2001 the 500 of TLRK, which to me is a bit of a mystery BT (but then, most of them are <g>). Four consecutive deals (ChemoCentryx, Protherics, Neogenesis and CRL) apparently designed to make their molecular science capability even bigger--CAMD from Protherics, small molecule drug candidates discovery tools, CRL's chemistry discovery platform, etc. TLRK already has a pretty full plate, what with cancer (where MZ cast some aspersion on its anti-tubilin binder), anti-folate; CMV; anti-infection (through TTP subsidiary); PPAR gamma for diabetes, obesity; inflammation and RA; and the Japan Tobacco program. Why the recent acquisition-related focus on additional molecular candidates and processes? In your view, and with the absence of new partner to co-develop one of TLRK's drug discovery programs, does this convey lack of belief in its existing pipe? Approx. $220 million in cash and equivalents as of 9/30/01; apparently nothing issued yet pursuant to the shelf filed this summer. Which of the company's programs grabbed your attention the most when you decided to add? Or was it enormous leverage, and serious downside risk. TLRK is old-time, rip-roaring biotech investing? <gg> (Your description of the founders and their objectives reminds me a bit of CRGN's founder/CEO profile and ambition.) Interested, of course, to know your thoughts. tia, quid